| INTRODUC TI ON
Immune checkpoint blockades (ICB) therapy have demonstrated durable antitumor effects in the treatment of non-small-cell lung cancer (NSCLC) and other tumors. [1] [2] [3] [4] Recent genomic mutation studies have elucidated potential driver genetic aberrations underlying NSCLC immune responses. [5] [6] [7] Cancer genomic and transcriptome features can contribute to the response to ICB such as higher tumor mutation burden (TMB), PD-L1 expression and interferon-γ (IFNγ)
signaling were correlated with survival benefits from anti-CTLA-4
and/or anti-PD-1 therapy. 5, 8, 9 Somatic mutations can cause the presence of tumor-specific neoantigen (neopeptide fragments), some of which with unique qualities serve as T-cell targets 10 and can be exploited to identify responders to immune checkpoint inhibitors. 11, 12 The mutational signatures are fingerprints of endogenous and exogenous factors that have acted over the course of tumorigenesis and heterogeneity. Smoking signatures and MMR signatures have been reported in immune responses in lung cancer patients. 6, 13 The APOBEC signature, characterized by C>T mutations at TpCpW (where W = A or T) trinucleotide sequences, has been found in bladder, breast, cervical, and non-small-cell lung cancers (NSCLCs), 14, 15 and attributed to the activity of the AID/APOBEC family of cytidine deaminases. 16 The APOBEC gene family have been found to be associated with interferon-associated anti-virus immunity activity.
17
Nevertheless, any possible association between the APOBEC mutational signature and the NSCLC immune response remains unknown.
Individual gene mutation may play a vital role in guiding immunotherapy. Recent studies have found that IFNGR1, a subunit of the IFN-γ receptor, acted in IFN-γ pathways and regulated the immune response. 18 Loss of function of PTEN was been previously reported to increase resistance to immune checkpoint blockade (ICB) in melanoma 19 and uterine leiomyosarcoma.
20
Features of the tumor microenvironment (TME) have been also associated with response to ICB therapy. Baseline levels of tumorinfiltrating CD8 + T cells and CD4 + T cells are correlated with the response to immune therapy. 21 Enriched genes involved in the pathways for IL2-STAT5, TNF-α signaling via NF-κB were also reported to have a connection with immunotherapy.
22
The purpose of this study was to characterize mutational signatures and prognosticators in patients diagnosed with NSCLC who were treated using ICB. The jointly interrogating NSCLC genomic data and clinical information were collected from published immune therapy studies. We consider that these findings may be applicable for guiding immunotherapy treatment for NSCLC patients.
| MATERIAL S AND ME THODS

| Genomic data and clinical information
Somatic mutations data (70 965 coding somatic mutations) for the aggregated immunotherapy cohort were acquired from recent publications [5] [6] [7] (Table S1 ). All previously called somatic mutations were re-annotated by oncotator 23 against hg19 reference genomics database. Both peptides resulting from wild-type and mutated sequences for predicted binding affinities scores below 500 nM to patient human leukocyte antigen (HLA) are defined as neoantigens (Table S2) . 6, 10 Patients with confirmed complete or partial response were considered to be responders; patients with stable disease, progressive disease, or not evaluable were considered to be non-responders. All patients had stage IV NSCLC and were treated by PD-1 or PD-1 plus CTLA-4 blockades. Detailed clinical information including age, gender, histological type, PD-L1 expression status (antibody and cutoff level), smoking status, ICB types, progression-free time, and status were also collected from these studies and are illustrated in Table S3 . The overall clinical characteristics were summarized and are listed in Table S4 . Somatic mutation, gene expression data and clinical information from 998 NSCLC samples (lung adenocarcinoma, n = 509; lung squamous-cell carcinoma, n = 489) in the Cancer Genome Atlas (TCGA) were downloaded from the Genome Data
Commons site (https ://portal.gdc.cancer.gov).
| Deciphering mutational signature operative in the genome
The framework advised by Kim et al 24, 25 was used to extract mutational signatures of aggregated samples (n = 113) and TCGA NSCLC cohorts. We used the framework based on Bayesian variant nonnegative matrix factorization that can automatically determine the optimal number of mutational signatures. The mutation portrait ma- 
| GSEA and network analysis
The The fast gene set enrichment analysis algorithm implemented in Bioconductor R package fgsea was used.
| Tumor-infiltrating lymphocyte cells analysis
CIBERSORT (http://ciber sort.stanf ord.edu/) was used to conduct the estimation of the abundances of tumor-infiltrating lymphocyte (TIL) cell types 30 with the gene expression profile of each patient.
Gene expression data of 250 low APOBEC signature activity samples and 250 high activity samples were also collected from TCGA.
| Statistical analyses
Statistical analyses in this study were generated by R-3.2.3.
Quantitative data are presented as the median. Continuous variables between groups were compared using the Mann-Whitney and EGFR findings were not statistically significance possibly due to small numbers (responder vs non-responder: TP53, 64.1% vs 48.6%; EGFR, 7.7% vs 14.9%, P > .05). In the current cohort, mutations in CD274 (PD-L1), B2M, and PTPN2 were all rare, occurring in only one patient with non-synonymous mutation (Figure 1 ).
| Mutational signatures operative in aggregated NSCLC cohort
To gain further insights into the mutational processes operative in responder vs non-responder, we delineated the mutation signatures from the somatic mutation data. The overall mutational pat- Figure 2C ).
| Mutational signatures correlated with the immune response
To identify mutagenic factors that are responsible for the immune response, logistic regression and survival analyses were performed to determine the relationship between mutation signatures and immune response. Of interest, we observed that patients with signature 2 (associated with APOBEC family of cytidine deaminases) were markedly associated with better immune responses. The objective response rate for NSCLC patients was 68.4% with the APOBEC signature vs 27.6% without the APOBEC signature, and the median progression-free survival was not reached (95% CI, 17.1 to NA) vs 5.9 mo (95% CI, 3.8-7.9), (HR, 0.27 [95% CI: 0.12-0.63], P = 0.002; log-rank test, P = .001, Figure 3A ). Figure 3C ) remained statistically significant. APOBEC mutational activities were strongly correlated with tumor mutation burden and neoantigen burden (TMB, Spearman's R = 0.59, P < .001, Figure S4 bottom; NB, Spearman's R = 0.54, P < .001; Figure S4 top). Furthermore, TMB and NB were greater in patients with the APOBEC signature than those without (TMB, median, 272 vs 160, P = .016, Figure 3D Figure S5 ).
| Further validation of APOBEC mutational signature in the TCGA cohort
Of the 998 patients with matched somatic mutation and gene expression data in the TCGA Project NSCLC cohort, 509 (51.0%) We also investigated the potential mechanism behind APOBEC mutagenesis signature and immunotherapy response. Gene set enrichment analysis (GSEA) on Hallmarker sets revealed that enrichment of genes involved in IL2-STAT5 signaling was significantly altered in samples with high mutational APOBEC activities, whereas MYC targets, PI3K-AKT-mTOR associated pathways were enriched in the low activities group (q < .001, Figures 4A and S7A ).
Furthermore, we found that immune checkpoint associated genes CD274 (PD-L1), LAG3, VTCN1 ( Figure S7B ) and antigen processing presentation associated genes TAP1, TAP2, PTPN2 ( Figure S7C) were also highly expressed in the high APOBEC mutation group.
Moreover, we evaluated (with use of the CIBER algorithm) the abundance of TIL cells in the NSCLC microenvironment using TCGA gene expression data. We found that CD8 + T cells, CD4 memory 
| D ISCUSS I ON
The development of anti-PD-1 and anti-CTLA-4 agents has revolutionized therapeutic strategies for NSCLC and multiple cancers.
However, the relationship between the genomic landscape and the benefit from immune therapy remains obscure. In patients with advanced NSCLC who were treated with ICB monotherapy, multiple reports have identified an association between increased TMB and NB with a likelihood of clinical benefit. 5, 6, 8 Combined TMB and APOBEC signatures may preferably predict responders in immunotherapy than using either signature alone (12 responders in 13 predict responding samples, positive predictive value, 92.3%). The mechanisms underlying the association between TMB and the APOBEC signature with immunotherapy is not entirely clear.
A leading hypothesis detailed that the mutation pattern of APOBEC drives a kataegic-like mutation signature and produces replication stress-associated chromosomal instability in cancers, 46, 47 suggesting that the APOBEC signature may concur with high somatic mutation.
Although we utilized multiple datasets for analysis, the only dataset that contained both whole-exome sequencing and RNA expression data was TCGA. As a result, association data between mutational patterns and gene expression, including analysis in immune cell infiltration and oncogenic pathways need further validation. In addition, the mutational activities of each signatures in TCGA and our datasets were differential distribution, for example the MMR signature 6 is significantly higher than TCGA cohort (signature 6:13.2% vs 2.8%, χ2 test, P < .001), signature 16 (16.5%) was observed exclusively in our aggregate datasets, and signature 5 (16.7%) exclusively in TCGA dataset. This difference may be because there was a higher proportion of squamous-cell carcinoma samples in TCGA than in the aggregated cohort (46% vs 19%; χ 2 test, P < .001).
In this study, we assembled and characterized genomic data and clinical information from 113 patients treated with ICB to determine whether tumor genetic landscape affects clinical benefit. These studies have identified putative a genomic mutation signature and molecular biomarkers in response to ICB, demonstrating the complex interplay of host and tumor in the treatment response. However, the mechanisms underlying the association between APOBEC signature with improved immunotherapy is still unclear and further studies in other cancer types are warranted.
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